Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China

OBJECTIVE: To establish non-inferiority of gonadotropin-releasing hormone degarelix compared with goserelin in suppressing and maintaining castrate testosterone levels from Day 28 to Day 364 in Chinese patients with prostate cancer. METHODS: This is an open-label, multi-centre study in which men age...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yinghao, Xie, Liping, Xu, Tao, Jakobsen, Jørn S., Han, Weiqing, Sørensen, Per S., Wang, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385516/
https://www.ncbi.nlm.nih.gov/pubmed/32742930
http://dx.doi.org/10.1016/j.ajur.2019.09.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385516/
https://www.ncbi.nlm.nih.gov/pubmed/32742930
http://dx.doi.org/10.1016/j.ajur.2019.09.003

Ejemplares similares